TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06063850: A Multi-center, Phase 1/2a, First-in-human (FIH) Study Investigating the Safety, Tolerability, and Efficacy of AMT-260 in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy (MTLE) Administered Via Magnetic Resonance Imaging (MRI)-Guided Convection-enhanced Delivery (CED)

Sponsor: UniQure Biopharma B.V. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,978,800

Rescue Site Savings

+$1,319,200

Unlock Full NCT06063850 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06063850 Rescue Dossier →